Search / Trial NCT00001218

Development of Normative Ultrasound Databases of Tongue Surface Configuration

Launched by NATIONAL INSTITUTES OF HEALTH CLINICAL CENTER (CC) · Dec 9, 2002

Apply for Trial

Trial Information

Current as of March 05, 2024

Completed

Keywords

Baseline Data Curve Averaging Curve Fitting Movement Patterns Normative Data Polar Distribution Tongue Tongue Shape Ultrasound

Description

Our past ultrasound research has indicated a need for baseline normative tongue data against which to compare our disordered speech populations. Subjects with normal speech and hearing who represent different ages and sexes, will be studied with respect to tongue shape and movement patterns. Recently developed parameters such as curve fitting, curve averaging, and polar coordinates will be used to create baseline data categories. In addition, new parameters and improved instruments will be developed as previously to produce a data base which can be used across disciplines.

Gender

All

Eligibility criteria

  • Healthy normal subjects.
  • No reconstructive tongue surgery.
  • No radiation for head and neck malignancy.

Attachments

readout_NCT00001218_2024-03-05.pdf

4.5 MB

NCT00001218_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0